Role of lymph node dissection in radical cystectomy

Wang,Keyi; Shi,Heng; Mao,Weipu; Yin,Lei; Wang,Guangchun; Fan,Donglai; Xie,Jinbo; Li,Weiyi; Peng,Bo

doi:10.3892/ol.2020.11563

Role of lymph node dissection in radical cystectomy

Authors:
- Keyi Wang
- Heng Shi
- Weipu Mao
- Lei Yin
- Guangchun Wang
- Donglai Fan
- Jinbo Xie
- Weiyi Li
- Bo Peng
View Affiliations

Affiliations: Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, P.R. China
Published online on: April 21, 2020 https://doi.org/10.3892/ol.2020.11563
Pages: 409-419
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The number of lymph node dissections (LNDs) is an independent factor influencing the survival time of patients with bladder cancer (BCa) after radical resection (RC). The present study aimed to investigate the association between the number of LNDs and the survival of patients with BCa at different stages and who underwent RC in the United States of America and China. Records from 17,730 American patients with BCa and 158 Chinese patients with BCa were collected from the Surveillance, Epidemiology and End Results (SEER) and the Shanghai Tenth People's Hospital (China) databases, respectively. Kaplan‑Meier curve and χ2 test were used to determine the overall survival time (OS) of patients with BCa. Cox regression analysis was used to analyze the effects of LND number on OS. Overall, 13,421 (75.7%) patients were negative for lymph node metastasis (N0) and 4,309 (24.3%) were positive for lymph node metastasis (N+) among the 17,730 American patients with BCa. In the group of 158 Chinese patients, 125 (79.1%) were N0 and 33 (20.9%) were N+. In the American patients, the median number of dissected nodes was 11.0 [interquartile range (IQR)=3.0‑21.0] for N0 patients and 14.0 (IQR=8.0‑23.0) for N+ patients. The median number of LNDs was 5.0 (IQR=2.0‑7.0) for Chinese N0 patients and 5.0 (IQR=1.5‑10.5) for Chinese N+ patients. The number of LNDs may therefore be an independent factor associated with survival in patients who underwent RC. Furthermore, a higher number of LNDs was associated with longer OS in patients with BCa [American patients, ≥13 nodes vs. ≤5 nodes, hazard ratio (HR)=0.62, 95% confidence interval (CI)=0.59‑0.65, P<0.001; Chinese patients, ≥5 nodes vs. ≤1 node, HR=0.27, 95% CI=0.12‑0.62, P=0.002]. The number of LNDs in patients with BCa and N+ was higher compared with number of LNDs in patients with BCa and N0 who underwent RC. More extensive LND improved the OS in both the patients from USA and China. Increasing the number of LNDs may therefore be crucial when treating patients with BCa.

View Figures

View References

1	Zhang ZF, Zhang HR, Zhang QY, Lai SY, Feng YZ, Zhou Y, Zheng SR, Shi R and Zhou JY: High expression of TMEM40 is associated with the malignant behavior and tumorigenesis in bladder cancer. J Transl Med. 16:92018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Czerniak B, Dinney C and McConkey D: Origins of bladder cancer. Ann Rev Pathol. 11:149–174. 2016. View Article : Google Scholar
4	Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S and Lotan Y: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
5	Mao W, Huang X, Wang L, Zhang Z, Liu M, Li Y, Luo M, Yao X, Fan J and Geng J: Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression. J Exp Clin Cancer Res. 38:1692019. View Article : Google Scholar : PubMed/NCBI
6	Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A and Palou-Redorta J; European Association of Urology (EAU), : EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 54:303–314. 2008. View Article : Google Scholar : PubMed/NCBI
7	Gupta NP, Goel R, Hemal AK, Dogra PN, Seth A, Aron M, Kumar R and Ansari MS: Radical cystectomy in septuagenarian patients with bladder cancer. Int Urol Nephrol. 36:353–358. 2004. View Article : Google Scholar : PubMed/NCBI
8	Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 71:462–475. 2017. View Article : Google Scholar : PubMed/NCBI
9	Konety BR, Joslyn SA and O'Donnell MA: Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the surveillance, epidemiology and end results program data base. J Urol. 169:946–950. 2003. View Article : Google Scholar : PubMed/NCBI
10	Siemens DR, Mackillop WJ, Peng Y, Wei X, Berman D and Booth CM: Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: A population-based study. Urol Oncol. 33:e415–e423. 2015. View Article : Google Scholar
11	May M, Herrmann E, Bolenz C, Tiemann A, Brookman-May S, Fritsche HM, Burger M, Buchner A, Gratzke C, Wülfing C, et al: Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol. 59:712–718. 2011. View Article : Google Scholar : PubMed/NCBI
12	Herr H, Lee C, Chang S and Lerner S; Bladder Cancer Collaborative G, : Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: A collaborative group report. J Urol. 171:1823–1828. 2004. View Article : Google Scholar : PubMed/NCBI
13	Hedgepeth RC, Zhang Y, Skolarus TA and Hollenbeck BK: Variation in use of lymph node dissection during radical cystectomy for bladder cancer. Urology. 77:7720112011. View Article : Google Scholar
14	Simone G, Papalia R, Ferriero M, Guaglianone S, Castelli E, Collura D, Muto G and Gallucci M: Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol. 20:390–397. 2013. View Article : Google Scholar : PubMed/NCBI
15	Bruins HM, Veskimae E, Hernandez V, Imamura M, Neuberger MM, Dahm P, Stewart F, Lam TB, N'Dow J, van der Heijden AG, et al: The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: A systematic review. Eur Urol. 66:1065–1077. 2014. View Article : Google Scholar : PubMed/NCBI
16	Cole AP, Dalela D, Hanske J, Mullane SA, Choueiri TK, Meyer CP, Nguyen PL, Menon M, Kibel AS, Preston MA, et al: Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 33:e509–e517. 2015. View Article : Google Scholar
17	Maruf M, Sidana A, Purnell S, Jain AL, Brancato SJ and Agarwal PK: Lymph node dissection during radical cystectomy following prior radiation therapy: Results from the SEER database. Int Urol Nephrol. 50:257–262. 2018. View Article : Google Scholar : PubMed/NCBI
18	Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, et al: Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: Survival results from a prospective, randomized trial. Eur Urol. 75:604–611. 2019. View Article : Google Scholar : PubMed/NCBI
19	Mao W, Ma B, Huang X, Gu S, Luo M, Fan J and Geng J: Which treatment is best for patients with AJCC stage IV bladder cancer? Int Urol Nephrol. 51:1145–1156. 2019. View Article : Google Scholar : PubMed/NCBI
20	Compton CC, Byrd DR, Garciaaguilar J, Kurtzman SH and Olawaiye A: AJCC Cancer Staging Atlas. Springer. (Berlin). 2012. View Article : Google Scholar
21	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
22	Leissner J, Hohenfellner R, Thuroff JW and Wolf HK: Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 85:817–823. 2000. View Article : Google Scholar : PubMed/NCBI
23	von Landenberg N, Speed JM, Cole AP, Seisen T, Lipsitz SR, Gild P, Menon M, Kibel AS, Roghmann F, Noldus J, et al: Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherap. Urol Oncol. 36:e13–e78. 2018. View Article : Google Scholar
24	Stabile A, Muttin F, Zamboni S, Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Capitanio U, Cucchiara V, Mazzone E, et al: Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Rev Anticancer Ther. 19:739–755. 2019. View Article : Google Scholar : PubMed/NCBI
25	Lee EK, Herr HW, Dickstein RJ, Kassouf W, Munsell MF, Grossman HB, Dinney CP and Kamat AM: Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int. 110:E590–E595. 2012. View Article : Google Scholar : PubMed/NCBI
26	Sharma M, Goto T, Yang Z and Miyamoto H: The impact of perivesical lymph node metastasis on clinical outcomes of bladder cancer patients undergoing radical cystectomy. BMC Urol. 19:772019. View Article : Google Scholar : PubMed/NCBI
27	Perera M, McGrath S, Sengupta S, Crozier J, Bolton D and Lawrentschuk N: Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer. Nat Rev Urol. 15:686–692. 2018. View Article : Google Scholar : PubMed/NCBI
28	Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE and Bajorin DF: Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 167:1295–1298. 2002. View Article : Google Scholar : PubMed/NCBI
29	Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S and Studer UE: Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 179:873–878. 2008. View Article : Google Scholar : PubMed/NCBI
30	Abol-Enein H, Tilki D, Mosbah A, El-Baz M, Shokeir A, Nabeeh A and Ghoneim MA: Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol. 60:572–577. 2011. View Article : Google Scholar : PubMed/NCBI
31	Poulsen AL, Horn T and Steven K: Radical cystectomy: Extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 160:2015–2019. 1998. View Article : Google Scholar : PubMed/NCBI
32	Koppie TM, Vickers AJ, Vora K, Dalbagni G and Bochner BH: Standardization of pelvic lymphadenectomy performed at radical cystectomy: Can we establish a minimum number of lymph nodes that should be removed? Cancer. 107:2368–2374. 2006. View Article : Google Scholar : PubMed/NCBI
33	Herr HW: Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology. 61:105–108. 2003. View Article : Google Scholar : PubMed/NCBI
34	Masson-Lecomte A, Vordos D, Hoznek A, Yiou R, Allory Y, Abbou CC, de la Taille A and Salomon L: External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy. Ann Surg Oncol. 20:1389–1394. 2013. View Article : Google Scholar : PubMed/NCBI
35	Crump K: The potential effects of recall bias and selection bias on the epidemiological evidence for the carcinogenicity of glyphosate. Risk Anal. 30:134402019.